One nanoparticle plus one antibody equals targeted drug delivery to tumors

July 15, 2013, National Cancer Institute

( —Herceptin and camptothecin are both powerful anticancer agents with key characteristics that limit their effectiveness in treating cancer. Patients treated with Herceptin, a monoclonal antibody that targets a growth promoting factor common to breast cancers (Her2), often relapse as their tumors become resistant to the drug. overcoming camptothecin"s toxicity and low solubility represent major therapeutic challenges. Now, researchers at the California Institute of Technology have used nanotechnology to combine the two into what so far appears to be a highly effective drug for treating aggressive breast cancer.

Mark E. Davis and his graduate student Han Han report their developmental work in the journal Molecular Pharmaceutics. Dr. Davis is also a project leader at Caltech's Center of Cancer Nanotechnology Excellence.

Drugs based on and nanoparticles are not new, but what Dr. Davis and Ms. Han have done for the first time is use a single antibody molecule, bound to a nanoparticle, as both a targeting agent for that drug-loaded nanoparticle and a therapeutic agent. They created this construct by first linking insoluble camptothecin to a natural biopolymer known as mucin and the widely used biocompatible polymer, (PEG). The camptothecin-mucin-PEG combination self-assembles into a tightly packed nanoparticle that readily dissolves in water and biological fluids such as blood. They then chemically linked one molecule of Herceptin per nanoparticle to create their final therapeutic agent.

In a previous study the group showed that a line of aggressive cells that overexpress the Her2 protein readily took up the Herceptin-linked nanoparticle. Based on these results, the Caltech researchers conducted tests in mice with tumors grown from this same cell line, which cancer researchers consider one of the most resistant cell lines to anticancer drugs, including camptothecin. First, they determined the maximum tolerated dose of the camptothecin nanoparticle drug without Herceptin, that is, the highest dose that would not cause the mice to lose more than 15 percent of their body weight. They then treated tumor-bearing animals with a dose of the Herceptin-bound nanoparticle that was approximately 10 percent of this maximum tolerated dose.

The results were impressive. All animals that received the Herceptin-camptothecin nanoparticle were free of any evidence of tumor by day nine of the experiment after a single injection, and the animals remained tumor-free at the end of the six week study (while being injected every three weeks). Animals treated with an equivalent amount of Herceptin alone every two weeks or untargeted camptothecin-loaded responded positively, with the majority of the treated mice showing significant tumor shrinkage, though only half the animals experienced complete tumor regression. Tumors grew rapidly with no signs of positive response in animals that received either saline or free camptothecin and none of the animals in those two groups survived to the end of the study.

This research, which is detailed in a paper titled, "Single-antibody, targeted nanoparticle delivery of camptothecin," was supported by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. An abstract of this paper is available at the journal's website.

Explore further: Biodegradable biopolymer nanoparticles hold promise for twin attack on breast cancer

Related Stories

Photo-immunotherapy boosts nanoparticle delivery to tumors

February 22, 2013

(—One of the main reasons that nanoparticles can boost the effectiveness of an anticancer drug while decreasing its toxicity is that they are able to accumulate at cancerous sites in the body through the abnormally ...

Polymer nanoparticle overcomes anticancer drug resistance

August 17, 2012

In a nanotechnology two-for-one, researchers at the Johns Hopkins University Center of Cancer Nanotechnology Excellence (Hopkins CCNE) have created a polymer nanoparticle that overcomes tumor resistance to the common anticancer ...

Overcoming cancer drug resistance with nanoparticles

January 20, 2012

One of the ways in which cancer cells evade anticancer therapy is by producing a protein that pumps drugs out of the cell before these compounds can exert their cell-killing effects. A research team at Northwestern University ...

Recommended for you

Sculpting stable structures in pure liquids

February 21, 2019

Oscillating flow and light pulses can be used to create reconfigurable architecture in liquid crystals. Materials scientists can carefully engineer concerted microfluidic flows and localized optothermal fields to achieve ...

Researchers make coldest quantum gas of molecules

February 21, 2019

JILA researchers have made a long-lived, record-cold gas of molecules that follow the wave patterns of quantum mechanics instead of the strictly particle nature of ordinary classical physics. The creation of this gas boosts ...

LMC S154 is a symbiotic recurrent nova, study suggests

February 21, 2019

Astronomers have conducted observations of a symbiotic star in the Large Magellanic Cloud (LMC), known as LMC S154, which provide new insights about the nature of this object. Results of these observations, presented in a ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.